Alphatec Holdings

Alphatec Holdings (NASDAQ: ATEC) is the Carlsbad California-based spine-surgery medical-device company that has been disrupting Medtronic, Stryker and Globus Medical (Nuvasive) in the lumbar and cervical fusion market since founder Pat Miles took over as CEO in 2017. The product platform combines proprietary implants and instruments with the EOS imaging system (full-body biplanar low-dose imaging) and the SafeOp Neural InformatiX System (real-time intraoperative nerve monitoring), creating an integrated workflow that no single competitor matches.

The 2025 revenue of 787 million dollars represented 13.6 percent organic growth, well ahead of the spine-surgery market growth rate of 3 to 4 percent, meaning ATEC continues to take share from incumbents. The stock peaked at 23.29 dollars in late 2024 on enthusiasm about path-to-GAAP-profitability, then crashed to a 52-week low of 6.82 dollars in early 2026 on dilutive convertible-note refinancing, weak Q3 2025 operating margin and a downbeat 2026 cash-burn outlook. The 5.1 percent 52-week-position reading captures a stock that has been left for dead by the market despite continued share-gain in the underlying business.

ATEC has unusually deep institutional sponsorship for a small-cap medical-device company. The largest active holders are Wellington Management (8.4 percent), Squarepoint Capital (5.2 percent), the dedicated medical-device specialist Janus Henderson (4.8 percent through their global life sciences fund), and the long-running healthcare boutique RA Capital Management (4.1 percent). The short interest at 8.95 percent of float is meaningful but is mostly a hedged offset to the institutional convertible holders rather than a directional bet.

Insider activity has been notable on the buy side. CEO Pat Miles added 175,000 shares at 7.10 dollars in March 2026 (a roughly 1.2 million dollar block), and Board Chair Mort Lukin added 100,000 shares at 7.40. This is a strong management-skin-in-the-game signal after the convertible dilution in February 2026. Pat Miles is the former Nuvasive COO who has put his reputation on the ATEC turnaround story since 2017, and he now owns approximately 4 percent of shares outstanding.

ATEC trades at 7.66 dollars with about 154 million fully-diluted shares outstanding, implying a 1.18 billion dollar market cap. Forward P/E of 13.3 times on the 2026 consensus EPS estimate of 0.58 dollars is misleadingly precise given the accounting volatility. EV-to-revenue at 2.0 times trailing is the more useful read, sitting at half the median for high-growth spine companies (Globus at 4.2x, NuVasive pre-merger 3.5x).

Among the 12 covering analysts, the consensus 12-month target is 17.33 dollars (126.28 percent upside), with the bull-case targets at 23 dollars from Piper Sandler and 22 dollars from Stifel anchored on 2027 GAAP-profitability inflection. If 2027 revenue reaches 1.0 billion dollars at 6 percent operating margin (15 percent normalized), implied EPS would approach 0.85 dollars, supporting a 18 to 22 dollar share price on 22 to 25 times P/E (typical for spine-disruptor names).

1. May 2026: Q1 2026 earnings (May 8). First quarter to fully reflect the February 2026 convert refinancing impact on interest costs, plus the first full quarter with EOSedge installed at over 200 hospital systems.
2. Sep 2026: NASS Annual Meeting Las Vegas. ATEC has historically used the North American Spine Society annual meeting to announce major product launches. Rumored next-generation SafeOp Stim wireless intraoperative monitoring system launch expected, supporting 2027 revenue acceleration.
3. Feb 2027: Q4 2026 and full-year results. First full quarter of GAAP operating profitability expected, which would trigger an inclusion screen for growth-at-reasonable-price (GARP) funds currently excluded by negative-earnings filters.

ATEC is a high-conviction asymmetric position for me. The combination of share-gain trajectory, FCF already positive, insider buying near 52-week low, and 126 percent average analyst upside is rare. The convertible-debt structure is the main reason the stock trades at this level, and once the 2026 conversion-pressure passes and 2027 GAAP profitability lands, the stock should re-rate to mid-teens at minimum.

I size ATEC at 1.5 to 2 percent of portfolio as a turnaround-spinout play. Downside is mid-teens drawdown if revenue growth disappoints to single-digits, but the franchise-quality and Pat Miles execution track record makes that unlikely. Upside is 100 to 130 percent over 18 months if growth holds and profitability inflection lands. This is exactly the kind of high-tracking-error name where institutional discomfort creates retail opportunity.